抗血素补充剂减弱了血中的肝素耐药性,在体外加了Gla无域因子Xa S195A
Yuko Mishima1, Amir L Butt1, Kofi B Vandyck1
1Department of Anesthesiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
British journal of anaesthesia
|April 9, 2024
概括
安德克萨尼特阿尔法 (GDXa) 在心脏手术患者中引起肝素耐药性. 在体外补充肝素和抗血可以通过恢复抗凝血和补偿失去的抑制剂来减轻这种抵抗.
科学领域:
- 心血管医学 心血管医学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 安德克萨内特阿尔法 (GDXa) 用于逆转直接口服抗凝剂.
- 接受心脏手术并暴露于GDXa的患者可能会发展出对肝素的耐药性.
- 有限的数据存在于用于GDXa诱导的氨酸耐药性的抗血使用.
研究的目的:
- 为了研究增加氨酸和抗血素水平在减弱GDXa诱导的氨酸耐药性的体外疗效.
- 评估GDXa对抗凝血和血栓生成的影响.
- 评估抗血在存在GDXa时恢复抗凝的作用.
主要方法:
- 正常的聚合血和心肺旁路血被GDXa上.
- 血栓生成试验评估了肝素逆转和抗凝固恢复.
- 测量包括氨酸-抗氨酸复合物,抗氨酸活性和组织因子通路抑制剂.
主要成果:
- 高氨酸和抗血水平在正常血中减轻了GDXa诱导的氨酸耐药性.
- 在心肺旁路血中,联合氨酸和抗血补充剂减弱了血生成变化超过70%.
- 这种补充也减少了氨酸-抗氨酸复合物的形成,但没有恢复组织因子通路抑制剂水平.
结论:
- 同时服用氨酸和抗血补充剂可以减轻GDXa诱导的氨酸耐药性.
- 这种综合方法补偿了组织因子通路抑制剂的损失.
- 这些发现表明,在暴露于GDXa的心脏手术患者中,管理肝素耐药性的潜在策略.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
689
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
689
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Extrinsic and Intrinsic Pathways of Hemostasis
7.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.4K
Clot Retraction and Fibrinolysis
5.7K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.7K
Disorders of Hemostasis
881
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
881


